Stealth Biotherapeutics doses first patient in Phase 2 study of elamipretide
Stealth announced that it has dosed the first patient in ReCLAIM-2, a Phase 2 study of elamipretide in patients with dry age-related macular degeneration with geographic atrophy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.